Eli Lilly and Company (NYSE:LLY) Shares Purchased by Mitchell Mcleod Pugh & Williams Inc.

Mitchell Mcleod Pugh & Williams Inc. lifted its stake in Eli Lilly and Company (NYSE:LLY) by 0.8% in the fourth quarter, HoldingsChannel reports. The firm owned 7,282 shares of the company’s stock after purchasing an additional 60 shares during the period. Eli Lilly and Company accounts for 1.1% of Mitchell Mcleod Pugh & Williams Inc.’s holdings, making the stock its 19th biggest position. Mitchell Mcleod Pugh & Williams Inc.’s holdings in Eli Lilly and Company were worth $4,245,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also modified their holdings of the company. Lipe & Dalton acquired a new position in shares of Eli Lilly and Company in the 4th quarter valued at $26,000. Thompson Investment Management Inc. acquired a new position in shares of Eli Lilly and Company in the 3rd quarter valued at $27,000. Legacy Financial Group LLC acquired a new position in shares of Eli Lilly and Company in the 3rd quarter valued at $35,000. Optiver Holding B.V. acquired a new position in shares of Eli Lilly and Company in the 3rd quarter valued at $36,000. Finally, Family CFO Inc acquired a new position in shares of Eli Lilly and Company in the 3rd quarter valued at $40,000. Institutional investors and hedge funds own 82.53% of the company’s stock.

Insider Transactions at Eli Lilly and Company

In other news, major shareholder Lilly Endowment Inc sold 78,573 shares of Eli Lilly and Company stock in a transaction dated Wednesday, January 31st. The stock was sold at an average price of $648.07, for a total value of $50,920,804.11. Following the transaction, the insider now owns 99,333,810 shares in the company, valued at $64,375,262,246.70. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Corporate insiders own 0.13% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on LLY. Truist Financial restated a “buy” rating and set a $850.00 price objective on shares of Eli Lilly and Company in a research report on Friday, March 22nd. Barclays lifted their price target on Eli Lilly and Company from $680.00 to $810.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 7th. JPMorgan Chase & Co. boosted their price objective on Eli Lilly and Company from $775.00 to $850.00 and gave the company an “overweight” rating in a research report on Friday, March 15th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $815.00 price target on shares of Eli Lilly and Company in a research note on Monday, April 15th. Finally, Wells Fargo & Company boosted their price objective on Eli Lilly and Company from $700.00 to $825.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 6th. Three investment analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $728.05.

Eli Lilly and Company Stock Down 0.1 %

LLY stock traded down $0.72 during trading on Monday, reaching $732.79. 613,577 shares of the stock were exchanged, compared to its average volume of 2,990,441. The firm’s 50 day moving average is $761.79 and its 200 day moving average is $667.10. Eli Lilly and Company has a twelve month low of $392.26 and a twelve month high of $800.78. The company has a current ratio of 0.94, a quick ratio of 0.73 and a debt-to-equity ratio of 1.69. The firm has a market cap of $696.27 billion, a P/E ratio of 127.22, a price-to-earnings-growth ratio of 1.60 and a beta of 0.34.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings data on Tuesday, February 6th. The company reported $2.49 EPS for the quarter, topping the consensus estimate of $2.30 by $0.19. Eli Lilly and Company had a return on equity of 51.22% and a net margin of 15.36%. The firm had revenue of $9.35 billion during the quarter, compared to the consensus estimate of $8.95 billion. During the same period in the prior year, the business posted $2.09 earnings per share. The company’s quarterly revenue was up 28.1% compared to the same quarter last year. As a group, research analysts forecast that Eli Lilly and Company will post 12.51 EPS for the current year.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.